FUNDING
Key Metrics
Company Snapshot
PureTech is a Biotech company, based in Boston, Massachusetts, USA, founded 2005 by Daphne Zohar. Market cap $0.42B (As of Sep 5, 2026, companiesmarketcap.com).
Recent changes
- Sep 5, 2026Sep 5, 2026First reported market cap: $0.42B companiesmarketcap.com
Latest Pulse
- Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
- Jul 2, 2026Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.→
Coverage Timeline
newest firstAll Coverage
FUNDING$180M Series B
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
FUNDING
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
FUNDING$180 million
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.
Related Companies
Sources & methodologyshow
Where these figures come from
- companiesmarketcap.comresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.